Robert J. Calcaterra

Embrex LLC manufactures agricultural and biological products. The company was founded by Harold V. Smith in 1985 and is headquartered in Parsippany, NJ.

EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA.

ZymeTx, Inc is a biotechnology company, which is engaged in the discovery, development and commercialization of products used to diagnose and treat viruses. The company's ViraZme technology focuses on the development of molecules that interacts with an enzyme of specific origin, such as viral, mammalian or bacterial origin. It was founded in 1994 and is headquartered in Oklahoma City, OK.

Purina Mills LLC produces and markets animal nutrition products. It manufactures and supplies livestock feed and pet food offering information concerning their products. The firm provides its products for commercial livestock and poultry, horse, bird, fish, zoo and pet industries. The company was founded on October 11, 2001 and is headquartered in Clayton, MO.

InterGenetics, Inc. researches and develops therapeutics for the prevention, diagnostics, and treatment of cancer. Its core research has future application in predicting heart disease, diabetes and in drug therapies and preventative medicine. The company was founded by Eldon R. Jupe, David A. Ralph and Craig D. Shimasaki in 1999 and is headquartered in Oklahoma City, OK.

Molecular Sensing, Inc. offers drug discovery services to pharmaceutical companies. Its drug discovery services include assay development, secondary screening, binding characterization process and pharmaceutical projects. The company was founded by Scot R. Weinberger and Darryl J. Bornhop in 2007 and is headquartered in Nashville, TN.

Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Wilkinson Sword Ltd. manufactures razors and disposables. The company was founded in 1889 and is headquartered in Bucks, the United Kingdom.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Part of AMETEK, Inc., Firefly Technologies, Inc. is a company that designs, develops, and manufactures heads and related products for the optical data storage and metrology industries. The company is based in Holliston, MA. Firefly Technologies was acquired by Zygo Corp., part of AMETEK, Inc. from June 23, 2014 on May 05, 2000 for $80.11 million.

Part of Merck KGaA, Linco Research, Inc. is a company based in St. Charles, MO. Linco Research, Inc. specializes in developing assays for diabetes and obesity research. Linco Research has introduced the LincoplexTM human cytokine kit for simultaneous multi-analyte detection and measurement of 11 cytokines. The company also offers analytical services and plan to expand their product offerings in the future. Linco Research is known for their gold standard products, including leptin RIA kits, insulin-specific assays, and rat insulin RIA kits. The company has a team of experienced staff who generate data quickly and efficiently. The company is committed to providing quality and unique analytical tests for advancements in diabetes and obesity research. Linco Research was acquired by Serologicals Corp. on May 02, 2006 for $64.50 million.

Wildwood Court, Inc. operates an independent insurance agency. Its products include personal lines, business lines, medical transportation, and public transportation insurance. The company was founded by John R. Tomassi in 1994 and is headquartered in Clifton Park, NY.

BioGenerator (Venture Capital) (BioGenerator) is a venture capital subsidiary of BioGenerator founded in 2003. The firm is headquartered in St. Louis, Missouri.

Jubilant Biosys Ltd. specializes in drug discovery services, proprietary in-house innovation, and strategic investments. Its services include discovery informatics, computational chemistry, structural biology, chemistry, in vitro and in vivo biology, and toxicology. The company was founded by VN Balaji in 2001 and is headquartered in Noida, India.

Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA.

Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri.

National Institutes of Allergy & Infectious Diseases develops therapies, vaccines and diagnostic tests for infectious diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Array Bridge, Inc. provides biotechnology research tools and services. It provides products and services in tow fields; Biological Development and Functional Proteomics. The Biological Development field provides cell line selection, process development, formulation development and change control to monitor the molecule’s safety and efficacy. The Functional Proteomics field develops PEP (Protein Elution Plate) technology that can measure protein functions from a proteome systematically. Array Bridge was founded by Xing Wang in 2010 and is headquartered in St. Louis, MO.

Apertus Pharmaceuticals LLC provides pharmaceutical manufacturing and analytical services. It offers compendial testing, API manufacturing, methods development and formulation, and drug discovery and preclinical development. The company is headquartered in Saint Louis, MO.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA.

Impetus Agriculture, LLC is an American company that specializes in growing commercial biotech crops and developing bio pesticide formulations. The company was founded in 2018, and Martha Schlicher has been the CEO of the company since 2020.

Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture.